Immunicum AB (publ) Receives Regenerative Medicine Advanced Therapy Designation from FDA for Ilixadencel in Kidney Cancer

What we doOur approachPipelineTechnologyPublications
About usExecutive ManagementBoard of DirectorsScientific Advisory Board
News & eventsPress releasesEventsInterviews
Investors
Careers

Back
Immunicum AB (publ) Receives Regenerative Medicine Advanced Therapy Designation from FDA  for Ilixadencel in Kidney Cancer
 8:00:00 AM

Keep reading
Immunicum AB (publ) Announces Peter Suenaert to Resume Role as Chief Medical OfficerRead